<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>AARTIPHARM</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">AARTIPHARM</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="aarti-pharmalabs-limited" class="section level1">
<h1>Aarti Pharmalabs Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.AARTIPHARM.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="comprehensive-analysis-of-aarti-pharmalabs-limited-aartipharm-scrip-543748-symbol-aartipharm" class="section level9">
<p class="heading"><strong>Comprehensive Analysis of Aarti Pharmalabs Limited (AARTIPHARM, Scrip: 543748, Symbol: AARTIPHARM)</strong></p>
<p><em>Based on Q2 FY26 Earnings Call (Nov 11, 2025), Regulatory Filings (Sep &amp; Oct 2025), and Company Communications</em></p>
<hr />
</div>
<div id="summary-overview" class="section level6">
<h6><strong>1. Summary Overview</strong></h6>
<p>Aarti Pharmalabs is a diversified pharmaceutical company with three main business verticals:<br />
- <strong>Xanthine Derivatives (51% of Q2 revenue)</strong><br />
- <strong>APIs &amp; Intermediates (39%)</strong><br />
- <strong>CDMO-CMO Services (10%)</strong></p>
<p>The company reported <strong>top-line growth (standalone: +11% YoY)</strong> but faced <strong>margin pressure</strong>, leading to lower EBITDA and PAT, mainly due to <strong>API business underperformance</strong> and <strong>forex losses</strong>. Management remains confident in <strong>FY26 guidance</strong> and long-term growth driven by <strong>capacity expansion (Atali plant)</strong>, <strong>CDMO traction</strong>, and <strong>strategic debottlenecking</strong>.</p>
<hr />
</div>
<div id="tailwinds-growth-drivers" class="section level6">
<h6><strong>2. Tailwinds (Growth Drivers)</strong></h6>
<div id="a.-strong-growth-in-cdmo-business" class="section level9">
<p class="heading"><strong>a. Strong Growth in CDMO Business</strong></p>
<ul>
<li>CDMO revenue is on track to <strong>exceed 30‚Äì40% YoY growth</strong>, a significant tailwind.</li>
<li><strong>59 active projects</strong> (39 commercial, 20 in development), with <strong>7‚Äì8 projects moved to commercial stage</strong> in H1 FY26.</li>
<li>Long-term visibility due to <strong>regulatory approvals (FDA, EDQM)</strong> and presence of <strong>large innovator partnerships</strong>.</li>
<li>Management confident in <strong>sustained growth</strong> due to strong project pipeline and focus on <strong>Phase 2‚Äì3 partnerships</strong>.</li>
<li>Geographical expansion with <strong>sales offices in Europe and planned presence in North America</strong> to boost new project funnel.</li>
</ul>
</div>
<div id="b.-xanthine-derivatives-performance-capacity-expansion" class="section level9">
<p class="heading"><strong>b. Xanthine Derivatives Performance &amp; Capacity Expansion</strong></p>
<ul>
<li>Xanthine segment contributed <strong>51% of revenue</strong> in Q2 FY26 and showed <strong>healthy volumes and margin improvement</strong>.</li>
<li><strong>Capacity increased to ~500 MT/month</strong> (9,000 MTPA by FY26-end).</li>
<li>Expansions at the Vapi site are <strong>brownfield and non-disruptive</strong>, allowing continuous production during upgrades.</li>
<li>Pricing has <strong>bottomed out and stabilized</strong>, reducing downside risk.</li>
<li>Company holds ~25% global market share ‚Äî a dominant position with potential to grow further.</li>
</ul>
</div>
<div id="c.-atali-facility-ramp-up-strategic-capex" class="section level9">
<p class="heading"><strong>c.¬†Atali Facility Ramp-Up (Strategic Capex)</strong></p>
<ul>
<li><strong>INR 440 crore investment</strong> in the Atali plant (55 km from Vapi), started operations in <strong>September 2025</strong>.</li>
<li>Adds <strong>440 KL capacity</strong> (340 KL already commercialized), freeing up Vapi site for higher-margin CDMO and API work.</li>
<li>Expected to <strong>enhance intermediate and CDMO capacity</strong>, enabling better product mix and volume growth from <strong>FY27 onward</strong>.</li>
<li>Allows <strong>better fungibility</strong> between businesses and supports long-term <strong>INR 1,000 crore revenue target</strong>.</li>
</ul>
</div>
<div id="d.-product-diversification-rd-pipeline" class="section level9">
<p class="heading"><strong>d.¬†Product Diversification &amp; R&amp;D Pipeline</strong></p>
<ul>
<li>Focus on <strong>anti-cancer and lifestyle APIs</strong>, with <strong>new product approvals expected in FY27‚ÄìFY28</strong>.</li>
<li>Debottlenecking of <strong>anti-cancer API block</strong> underway, enabling better fulfillment of upcoming launches.</li>
<li>Exploring <strong>peptide synthesis capabilities</strong> (mid-size, liquid-phase), opening up new revenue streams.</li>
</ul>
</div>
<div id="e.-margin-improvement-potential" class="section level9">
<p class="heading"><strong>e. Margin Improvement Potential</strong></p>
<ul>
<li>CDMO and Xanthine have <strong>structurally higher margins</strong> than generic APIs.</li>
<li>As <strong>CDMO mix increases</strong> and <strong>API mix normalizes</strong>, <strong>overall EBITDA margin should improve</strong> in the mid-to-long term.</li>
<li>Company aims to <strong>reduce reliance on volatile generic launches</strong> and improve stability through <strong>contract manufacturing and long-term projects</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>3. Headwinds (Challenges)</strong></h6>
<div id="a.-api-business-underperformance" class="section level9">
<p class="heading"><strong>a. API Business Underperformance</strong></p>
<ul>
<li><strong>API revenue declined YoY</strong> (consolidated: INR 458 cr ‚Üí INR 418 cr in Q2), due to:
<ul>
<li><strong>Inventory correction</strong> by customers (high stockpiles from FY25).</li>
<li><strong>Increased competition</strong> and <strong>pricing pressure</strong>, especially in <strong>hyper-intensive and respiratory molecules</strong>.</li>
</ul></li>
<li>Margin dilution in FY26 due to a <strong>less-favorable product mix</strong>.</li>
<li>Previous year‚Äôs strong growth due to <strong>favorable margin launches</strong>, which are now facing <strong>genericization headwinds</strong>.</li>
</ul>
</div>
<div id="b.-margin-compression" class="section level9">
<p class="heading"><strong>b. Margin Compression</strong></p>
<ul>
<li><strong>Gross and EBITDA margins down YoY and QoQ</strong>:
<ul>
<li>Standalone EBITDA: INR 85 cr ‚Üí INR 75 cr (Sep 2024 ‚Üí Sep 2025).</li>
<li>PAT: INR 48 cr ‚Üí INR 31 cr (Standalone).</li>
</ul></li>
<li>Impact due to:
<ul>
<li><strong>Capacity constraints</strong>: Vapi site too focused on CDMO intermediate production.</li>
<li><strong>Higher costs</strong> from facility upgrades and solar power seasonality.</li>
<li>Lower-margin API mix.</li>
</ul></li>
</ul>
</div>
<div id="c.-forex-losses" class="section level9">
<p class="heading"><strong>c.¬†Forex Losses</strong></p>
<ul>
<li><strong>INR 7.4 crore forex loss</strong> in Q2 due to <strong>INR depreciation (~INR 3 vs USD)</strong> in Q2.</li>
<li>Company holds <strong>$24 million in foreign currency loans</strong>.</li>
<li><strong>Hedging policy</strong>: Management prefers <strong>no hedging (forex open)</strong> to avoid hedging costs, but this exposes P&amp;L to currency volatility.</li>
</ul>
</div>
<div id="d.-working-capital-pressure" class="section level9">
<p class="heading"><strong>d.¬†Working Capital Pressure</strong></p>
<ul>
<li><strong>Inventories up</strong> to INR 625 crore (from ~INR 550 crore in FY25 end), mainly due to:
<ul>
<li><strong>CDMO batch manufacturing</strong> requiring multi-stage inventory buildup.</li>
</ul></li>
<li>Debt increased in short term, though this is expected to normalize post-revenue recognition.</li>
</ul>
</div>
<div id="e.-regulatory-risk-patent-litigation" class="section level9">
<p class="heading"><strong>e. Regulatory Risk: Patent Litigation</strong></p>
<ul>
<li><strong>Ex-parte injunction from Delhi High Court (Oct 7, 2025)</strong>:
<ul>
<li>Restrains manufacturing/selling <strong>Ruxolitinib/Ruxolitinib Phosphate API</strong>.</li>
<li>Patent involved: <strong>IN269841</strong> (Heteroaryl Substituted Pyrrolo[2,3-b]pyridines).</li>
</ul></li>
<li><strong>Annexure A confirms</strong> no <strong>financial impact so far</strong>, but:
<ul>
<li>Risk of <strong>future penalties or permanent injunction</strong>.</li>
<li>Potential <strong>reputational risk</strong>.</li>
<li>Business operations unaffected as of now, but <strong>product in question may contribute to API portfolio</strong>.</li>
</ul></li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-outlook" class="section level6">
<h6><strong>4. Growth Prospects &amp; Strategic Outlook</strong></h6>
<table>
<colgroup>
<col width="55%" />
<col width="44%" />
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Expectation / Status</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue Target (Next 2‚Äì3 years)</strong></td>
<td><strong>INR 1,000 crore</strong> total revenue, driven by CDMO and Xanthine</td>
</tr>
<tr class="even">
<td><strong>API Growth</strong></td>
<td>Challenging in FY26; recovery expected in <strong>FY27‚ÄìFY28</strong> with new anti-cancer launches</td>
</tr>
<tr class="odd">
<td><strong>CDMO Growth</strong></td>
<td><strong>30‚Äì40%+ YoY growth in FY26</strong>, with acceleration beyond FY27 as Atali ramps up</td>
</tr>
<tr class="even">
<td><strong>Xanthine Growth</strong></td>
<td><strong>Volume-driven</strong>, stable pricing, expanding capacity to 9,000 MTPA</td>
</tr>
<tr class="odd">
<td><strong>EBITDA Guidance FY26</strong></td>
<td><strong>8‚Äì12% YoY growth</strong> (after Atali-related cost absorption)</td>
</tr>
<tr class="even">
<td><strong>Long-Term EBITDA Growth</strong></td>
<td><strong>15‚Äì20% not feasible;</strong> PAT growth more likely, EBITDA depends on large launches</td>
</tr>
<tr class="odd">
<td><strong>Working Capital</strong></td>
<td>Should <strong>normalize in H2</strong> as CDMO sales are recognized</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6><strong>5. Key Risks</strong></h6>
<div id="a.-business-market-risks" class="section level9">
<p class="heading"><strong>a. Business &amp; Market Risks</strong></p>
<ul>
<li><strong>Volatility in API pricing and demand</strong>, especially for newly launched generics.</li>
<li><strong>Reliance on innovator strategies</strong> ‚Äî sales depend on customer launch plans.</li>
<li><strong>Long gestation in CDMO</strong> ‚Äî revenue lags project ramp-up; not immediately accretive.</li>
<li><strong>Capacity constraints</strong> before Atali full ramp-up.</li>
</ul>
</div>
<div id="b.-financial-risks" class="section level9">
<p class="heading"><strong>b. Financial Risks</strong></p>
<ul>
<li><strong>Forex exposure</strong> due to unhedged foreign currency debt ‚Üí <strong>P&amp;L volatility</strong>.</li>
<li><strong>Capex and depreciation impact</strong> from Atali project starting in Q3 FY26.</li>
<li><strong>Working capital buildup</strong> from multi-stage CDMO production.</li>
</ul>
</div>
<div id="c.-regulatory-legal-risks" class="section level9">
<p class="heading"><strong>c.¬†Regulatory &amp; Legal Risks</strong></p>
<ul>
<li><strong>Ongoing patent litigation</strong> for Ruxolitinib ‚Äì potential for <strong>commercial restrictions</strong> or <strong>royalty liabilities</strong>.</li>
<li>Risk of <strong>additional litigation</strong> if other products face patent challenges.</li>
</ul>
</div>
<div id="d.-operational-risks" class="section level9">
<p class="heading"><strong>d.¬†Operational Risks</strong></p>
<ul>
<li><strong>Delayed ramp-up</strong> at Atali plant due to validation or regulatory clearances.</li>
<li><strong>Dependency on key customers</strong>, especially in CDMO and Xanthine.</li>
</ul>
<hr />
</div>
</div>
<div id="conclusion-investment-thesis" class="section level6">
<h6><strong>6. Conclusion: Investment Thesis</strong></h6>
<div id="positive-buyhold-with-growth-potential" class="section level9">
<p class="heading"><strong>Positive (BUY/HOLD with growth potential)</strong></p>
<p>‚úÖ Strong CDMO momentum with <strong>high-growth, long-term contracts</strong><br />
‚úÖ Xanthine segment <strong>stable and expanding</strong>, with <strong>dominant market share</strong><br />
‚úÖ <strong>Atali plant</strong> to de-risk capacity and enable future revenue scaling<br />
‚úÖ Strategic shift toward <strong>higher-margin, less commoditized products</strong></p>
</div>
<div id="concerns-caution" class="section level9">
<p class="heading"><strong>Concerns (CAUTION)</strong></p>
<p>‚ö†Ô∏è <strong>API volatility</strong> and <strong>margin pressure</strong> in near term<br />
‚ö†Ô∏è <strong>Forex risk</strong> and <strong>working capital inefficiency</strong> in H1<br />
‚ö†Ô∏è <strong>Pending litigation</strong> ‚Äî low impact today, but <strong>requires monitoring</strong><br />
‚ö†Ô∏è <strong>EBITDA margin uncertain</strong> ‚Äî depends on API recovery and product mix</p>
</div>
<div id="outlook" class="section level9">
<p class="heading"><strong>Outlook</strong></p>
<ul>
<li><strong>H2 FY26 should show strong recovery</strong> in EBITDA due to <strong>CDMO sales recognition</strong> and <strong>API normalization</strong>.</li>
<li><strong>FY27 onwards</strong>, <strong>Atali and new API launches</strong> should drive multi-year growth.</li>
<li><strong>CDMO to become key revenue driver</strong> by FY28.</li>
<li><strong>Fairly positioned for INR 1,000 crore revenue by FY28</strong>, though dependent on execution.</li>
</ul>
<hr />
</div>
</div>
<div id="final-rating-accumulate-hold-with-a-long-term-view" class="section level6">
<h6><strong>Final Rating: </strong>üü¢ <strong>Accumulate / Hold with a Long-Term View</strong></h6>
<ul>
<li><strong>Catalysts Ahead</strong>: CDMO commercialization, anti-cancer API launches, Atali ramp-up.</li>
<li><strong>De-risked after H1 FY26 weakness</strong>; patient investors likely to benefit from FY27 onward.</li>
<li>Monitor: <strong>Litigation outcome</strong>, <strong>FX movement</strong>, and <strong>Q3 capex/expense absorption</strong>.</li>
</ul>
<hr />
<p><strong>Prepared on: November 20, 2025</strong><br />
<em>Based solely on publicly disclosed documents and earnings call transcript of Aarti Pharmalabs Limited (AARTIPHARM)</em>.</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
